Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CAR-T Cell”

1,934 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,934 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04416984
What this trial is testing

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Who this might be right for
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Allogene Therapeutics 160
Very early researchUnknownNCT04186052
What this trial is testing

Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma

Who this might be right for
Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)Active Not RecruitingNCT04629729
What this trial is testing

FT819 in Subjects With B-cell Malignancies

Who this might be right for
Lymphoma, B-CellChronic Lymphocytic LeukemiaPrecursor B-Cell Acute Lymphoblastic Leukemia
Fate Therapeutics 54
Testing effectiveness (Phase 2)Looking for participantsNCT06097832
What this trial is testing

Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Who this might be right for
Light Chain (AL) Amyloidosis
Nexcella Inc. 40
Very early researchActive Not RecruitingNCT06574958
What this trial is testing

Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma

Who this might be right for
ORR,OS,PFS
The Second Hospital of Shandong University 10
Early research (Phase 1)Looking for participantsNCT07172958
What this trial is testing

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Who this might be right for
RhabdomyosarcomaEwing SarcomaNeuroblastoma+1 more
Children's National Research Institute 18
Testing effectiveness (Phase 2)Study completedNCT06556108
What this trial is testing

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Xinqiao Hospital of Chongqing 5
Testing effectiveness (Phase 2)Looking for participantsNCT06323525
What this trial is testing

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Who this might be right for
Non-hodgkin Lymphoma
Chinese PLA General Hospital 30
Early research (Phase 1)Looking for participantsNCT05990621
What this trial is testing

Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms

Who this might be right for
CD70-positive Advanced Urologic Neoplasms
Changhai Hospital 60
Early research (Phase 1)Study completedNCT02765243
What this trial is testing

Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma

Who this might be right for
NeuroblastomaEffects of Immunotherapy
Zhujiang Hospital 12
Testing effectiveness (Phase 2)UnknownNCT04715217
What this trial is testing

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Shanxi Province Cancer Hospital 24
Very early researchActive Not RecruitingNCT05302648
What this trial is testing

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM

Who this might be right for
Multiple Myeloma
Hrain Biotechnology Co., Ltd. 18
Very early researchStudy completedNCT03825718
What this trial is testing

GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Hebei Yanda Ludaopei Hospital 29
Large-scale testing (Phase 3)Looking for participantsNCT06799247
What this trial is testing

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

Who this might be right for
Myasthaenia Gravis
Cartesian Therapeutics 100
Early research (Phase 1)Looking for participantsNCT04881240
What this trial is testing

Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia, RefractoryPediatric ALL
St. Jude Children's Research Hospital 60
Testing effectiveness (Phase 2)UnknownNCT02963038
What this trial is testing

CAR T Cells for Refractory B Cell Malignancy

Who this might be right for
B-Cell LeukemiaB-Cell Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT05767359
What this trial is testing

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Who this might be right for
Multiple MyelomaSmoldering Multiple Myeloma
Dana-Farber Cancer Institute 20
Testing effectiveness (Phase 2)Looking for participantsNCT06589089
What this trial is testing

Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy

Who this might be right for
Diffuse Large B Cell Lymphoma
Ruijin Hospital 18
Not applicableLooking for participantsNCT06503224
What this trial is testing

An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
The First Affiliated Hospital of University of Science and Technology of China 18
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Load More Results